Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).

被引：0
|
作者：
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Wittenberger, Kathleen
Molnar, Levente
Lorincz, Orsolya
Somogyi, Eszter
Csiszovszki, Zsolt
Youssoufian, Hagop
Toke, Eniko Rita
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin Arizona, Phoenix, AZ USA
[3] Mayo Clin, Jacksonville, FL USA
[4] Treos Bio, Veszprem, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS283
引用
收藏
页码：TPS283 / TPS283
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
    Liao, Wangjun
    Shi, Min
    Rong, Xiaoxiang
    Zheng, Siting
    Li, Shaowei
    Peng, Weiwei
    Wang, Xiangcai
    Yuan, Xia
    Zeng, Wei
    Wang, Chunlin
    Deng, Qiong
    Zhang, Futing
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 166 - 166
  • [42] Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)
    Buecklein, Veit L.
    Warm, Maximilian
    Spiekermann, Karsten
    Schmidt, Christian
    Unterhalt, Michael
    Daver, Naval
    Subklewe, Marion
    BLOOD, 2022, 140 : 3227 - 3228
  • [43] Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
    Fang, Xuefeng
    Zhu, Ning
    Zhong, Chenhan
    Wang, Liuhong
    Li, Jun
    Weng, Shanshan
    Hu, Hanguang
    Dong, Caixia
    Li, Dan
    Song, Yongmao
    Xu, Dong
    Wang, Jianwei
    Sun, Lifeng
    Wang, Jian
    Wang, Zhanhuai
    Cao, Hongfeng
    Liao, Xiujun
    Yu, Ningjuan
    Xiao, Qian
    Mi, Mi
    Zhang, Suzhan
    Ding, Kefeng
    Yuan, Ying
    ECLINICALMEDICINE, 2023, 62
  • [44] Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
    Fenner, Martin
    Oing, Christoph
    Dieing, Annette
    Gauler, Thomas
    Oechsle, Karin
    Lorch, Anja
    Hentrich, Marcus
    Kopp, Hans-Georg
    Bokemeyer, Carsten
    Honecker, Friedemann
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (03) : 717 - 723
  • [45] Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
    Martin Fenner
    Christoph Oing
    Annette Dieing
    Thomas Gauler
    Karin Oechsle
    Anja Lorch
    Marcus Hentrich
    Hans-Georg Kopp
    Carsten Bokemeyer
    Friedemann Honecker
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 717 - 723
  • [46] Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9
    Lee, James J.
    Yothers, Greg
    George, Thomas J.
    Fakih, Marwan G.
    Mallick, Atrayee Basu
    Mitchell, Edith P.
    Wade, James L.
    Krauss, John C.
    Kayaleh, Omar R.
    Heron, Dwight E.
    Allegra, Carmen J.
    Lipchik, Corey
    Feng, Huichen
    Joy, Marion
    Srinivasan, Ashok
    Pogue-Geile, Katherine L.
    Lucas, Peter C.
    Warren, Sarah E.
    Cesano, Alessandra
    Jacobs, Samuel A.
    CANCER RESEARCH, 2019, 79 (13)
  • [47] NSABP FC-9: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (D) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy
    Lee, James J.
    Yothers, Greg
    George, Thomas J.
    Fakih, Marwan
    Mallick, Atrayee Basu
    Maalouf, Bassam Nabih
    Krauss, John C.
    Heron, Dwight Earl
    Allegra, Carmen Joseph
    Jacobs, Samuel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01
    Yoshino, T.
    Siena, S.
    Di Bartolomeo, M.
    Raghav, K.
    Masuishi, T.
    Loupakis, F.
    Kawakami, H.
    Yamaguchi, K.
    Nishina, T.
    Fakih, M.
    Elez, E.
    Rodriguez, J.
    Ciardiello, F.
    Saxena, K.
    Yamamoto, E.
    Kobayashi, K.
    Bako, E.
    Okuda, Y.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1275 - S1275
  • [49] An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC).
    Yu, Yongfeng
    Huang, Dingzhi
    Pan, Hongming
    Li, Chun-lai
    Wang, Sheng
    Guo, Hai-jun
    Su, Rong
    Zhang, Li-qin
    Li, Shi-chang
    Wang, Yi-wei
    Hei, Yong-Jiang
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Pooled safety results from SPIRITT: A multicenter, open-label, randomized, phase II study of FOLFIRI with panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
    Hecht, J. R.
    Dakhil, S. R.
    Saleh, M. N.
    Piperdi, B.
    Cline-Burkhardt, M.
    Kocs, D. M.
    DeMarco, L. C.
    Chen, L.
    Krishnan, K.
    Cohn, A. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345